RXi Pharmaceuticals and the Center for Cancer Immune Therapy at Herlev Hospital Announce Research Collaboration

MARLBOROUGH, Mass., Dec. 1, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company developing a new class of RNAi-based therapeutics and the Center for Cancer Immune Therapy (CCIT) at Herlev Hospital, a leading European center for use of tumor infiltrating lymphocytes (TIL) for adoptive T-cell therapy (ACT), today announced that they have entered into a collaborative research agreement to evaluate the potential of RXi's novel self-delivering RNAi (sd-rxRNA®) technology platform in TILs for the use in treatment for a number of cancer types, including melanoma and ovarian cancer.

Logo: http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg

Dr. Karen Bulock, Vice President of Research at RXi Pharmaceuticals said, "Immunotherapy treatments have shown significant promise in extending the lifespan of previously untreatable cancer patients.  We are excited to work with the extraordinary scientific leaders at the CCIT to evaluate the advantages of our therapeutic sd-rxRNA compounds in various cancer models."  She further added that, "This research collaboration, in combination with other collaborations we have announced, are going to be key cornerstones in our efforts to translate positive results into a clinical setting which we hope to achieve within the next 12-18 months." 

Professor and Director at CCIT, Inge Marie Svane, MD, Ph.D., said that, "Over the course of the last few years, the CCIT has carried out numerous clinical trials based on a direct translation of the discoveries from the laboratory. We are excited to test the potential of RXi's innovative self-delivering RNAi technology platform to potentiate TILs for ACT." 

About Center for Cancer Immune Therapy at Herlev Hospital

Established in October 2006, the CCIT is a fusion between the Tumor Immunology Group, Danish Cancer Society and the Immunotherapy Group, Copenhagen University Hospital, Herlev. CCIT aims to bridge the gap between discovery and clinical implementation in the field of cancer immunotherapy. CCIT has a focus on the development of immunological treatment of cancer and has a research profile based on equally weighted experimental and clinical projects facilitating quick clinical implementation of new immunotherapies. It is the leading European center for the use of tumor infiltrating lymphocytes (TIL) for adoptive T-cell therapy (ACT) for metastatic melanoma. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic cellular products and evaluations of immune responses.  For additional information, visit the CCIT website www.herlevhospital.dk/ccit-denmark   

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology, and cell-based immunotherapy.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. For additional information, visit the Company's website, www.rxipharma.com. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact  
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646

SOURCE RXi Pharmaceuticals Corporation

Related Links

http://www.rxipharma.com